Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Missed Opportunities for Engagement in the Prevention Continuum in a Predominantly Black and Latino Community in New York City.

Zucker J, Patterson B, Ellman T, Slowikowski J, Olender S, Gordon P, Morrison EAB, Sobieszczyk ME.

AIDS Patient Care STDS. 2018 Nov;32(11):432-437. doi: 10.1089/apc.2018.0127.

PMID:
30398951
2.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HVN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM; NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team.

PLoS One. 2018 Sep 20;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018.

3.

Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.

McPherson TD, Sobieszczyk ME, Markowitz M.

Expert Opin Investig Drugs. 2018 Apr;27(4):413-420. doi: 10.1080/13543784.2018.1460357. Epub 2018 Apr 10. Review.

PMID:
29633869
4.

Positive or Not, That Is the Question: HIV Testing for Individuals on Pre-exposure Prophylaxis.

Zucker J, Carnevale C, Rai AJ, Gordon P, Sobieszczyk ME.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):e11-e13. doi: 10.1097/QAI.0000000000001665. No abstract available.

PMID:
29481487
5.

Knowledge of tuberculosis and vaccine trial preparedness in Lima, Peru.

Shu E, Sobieszczyk ME, Sal Y Rosas VG, Segura P, Galea JT, Lecca L, Sanchez J, Lama JR.

Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1288-1293. doi: 10.5588/ijtld.17.0116.

PMID:
29297450
6.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

7.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network.

PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435. eCollection 2017 Nov.

8.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

9.

Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants.

Meyers K, Rodriguez K, Brill AL, Wu Y, La Mar M, Dunbar D, Koblin B, Margolis D, Sobieszczyk ME, Van Tieu H, Frank I, Markowitz M, Golub SA.

AIDS Behav. 2018 Apr;22(4):1209-1216. doi: 10.1007/s10461-017-1871-x.

PMID:
28744666
10.

Lactobacillus rhamnosus Endocarditis After Upper Endoscopy.

Aaron JG, Sobieszczyk ME, Weiner SD, Whittier S, Lowy FD.

Open Forum Infect Dis. 2017 May 2;4(2):ofx085. doi: 10.1093/ofid/ofx085. eCollection 2017 Spring.

11.

Malnutrition in HIV-Infected Children Is an Indicator of Severe Disease with an Impaired Response to Antiretroviral Therapy.

Muenchhoff M, Healy M, Singh R, Roider J, Groll A, Kindra C, Sibaya T, Moonsamy A, McGregor C, Phan MQ, Palma A, Kloverpris H, Leslie A, Bobat R, LaRussa P, Ndung'u T, Goulder P, Sobieszczyk ME, Archary M.

AIDS Res Hum Retroviruses. 2018 Jan;34(1):46-55. doi: 10.1089/AID.2016.0261. Epub 2017 Sep 6.

12.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR.

Lancet HIV. 2017 Aug;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1. Epub 2017 May 22.

PMID:
28546090
13.

Metabolic Syndrome After HIV Acquisition in South African Women.

Sobieszczyk ME, Werner L, Mlisana K, Naicker N, Feinstein A, Gray CM, Masson L, Passmore JS, Williamson C, Abdool Karim Q, Abdool Karim SS, Garrett NJ.

J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):438-445.

PMID:
27391387
14.

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, DeRosa SC, Tomaras GD, Wagner TM, Baden LR, Koblin BA, Rouphael NG, Kalams SA, Keefer MC, Goepfert PA, Sobieszczyk ME, Mayer KH, Swann E, Liao HX, Haynes BF, Graham BS, McElrath MJ; NIAID HIV Vaccine Trials Network.

J AIDS Clin Res. 2015 May;6(5). pii: 461. Epub 2015 May 23.

15.

Using conjoint analysis to determine the impact of product and user characteristics on acceptability of rectal microbicides for HIV prevention among Peruvian men who have sex with men.

Tang EC, Galea JT, Kinsler JJ, Gonzales P, Sobieszczyk ME, Sanchez J, Lama JR.

Sex Transm Infect. 2016 May;92(3):200-5. doi: 10.1136/sextrans-2015-052028. Epub 2015 Nov 16.

PMID:
26574569
16.

Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.

Ellman TM, Hawkins K, Benitez J, Negron R, Chang S, Palmer S, Robertson V, Chiasson MA, Sobieszczyk ME.

Vaccine. 2015 Nov 27;33(48):6809-15. doi: 10.1016/j.vaccine.2015.09.091. Epub 2015 Oct 11.

17.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

18.

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.

Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF.

Science. 2015 Aug 14;349(6249):aab1253. doi: 10.1126/science.aab1253. Epub 2015 Jul 30.

19.

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.

Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME; NIAID HIV Vaccine Trials Network.

Clin Trials. 2015 Aug;12(4):394-402. doi: 10.1177/1740774515579165. Epub 2015 Apr 7.

20.

Recruitment by a geospatial networking application for research and practice: the New York City experience.

Usher D, Frye V, Shinnick J, Greene E, Baez E, Benitez J, Solomon L, Shouse RL, Sobieszczyk ME, Koblin BA.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):e143-5. doi: 10.1097/QAI.0000000000000366. No abstract available.

21.

A forgotten population: older adults with newly diagnosed HIV.

Ellman TM, Sexton ME, Warshafsky D, Sobieszczyk ME, Morrison EA.

AIDS Patient Care STDS. 2014 Oct;28(10):530-6. doi: 10.1089/apc.2014.0152. Epub 2014 Sep 11.

PMID:
25211596
22.

Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru.

Tang EC, Sobieszczyk ME, Shu E, Gonzales P, Sanchez J, Lama JR.

AIDS Res Hum Retroviruses. 2014 May;30(5):416-24. doi: 10.1089/AID.2013.0212. Epub 2014 Jan 20.

23.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

24.

Translational research insights from completed HIV vaccine efficacy trials.

Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S150-4. doi: 10.1097/QAI.0b013e31829a3985. Review.

PMID:
23764628
25.

Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.

Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B, Hammer S; HVTN 505 Protocol Team.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):259-62. doi: 10.1097/QAI.0b013e318296df94.

26.

In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.

Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1513-23. doi: 10.1089/AID.2012.0385. Epub 2013 Jun 25.

27.

Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.

Etter P, Landovitz R, Sibeko S, Sobieszczyk ME, Riddler SA, Karg C, Tsibris A, Schouten J.

AIDS. 2013 Apr 24;27(7):1119-28. doi: 10.1097/QAD.0b013e32835dc08e. Review.

28.

HIV serostatus disclosure is not associated with safer sexual behavior among HIV-positive men who have sex with men (MSM) and their partners at risk for infection in Bangkok, Thailand.

Edwards-Jackson N, Phanuphak N, Van Tieu H, Chomchey N, Teeratakulpisarn N, Sathienthammawit W, Pakam C, Pharachetsakul N, Sobieszczyk ME, Phanuphak P, Ananworanich J.

AIDS Res Ther. 2012 Dec 23;9(1):38. doi: 10.1186/1742-6405-9-38.

29.

HIV prevention in high-risk women in South Africa: condom use and the need for change.

van Loggerenberg F, Dieter AA, Sobieszczyk ME, Werner L, Grobler A, Mlisana K; CAPRISA 002 Acute Infection Study Team.

PLoS One. 2012;7(2):e30669. doi: 10.1371/journal.pone.0030669. Epub 2012 Feb 17.

30.

Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.

Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R; NIAID HIV Vaccine Trials Network 044 Study Team.

J Infect Dis. 2011 Nov 15;204(10):1541-9. doi: 10.1093/infdis/jir615. Epub 2011 Sep 21.

31.

Host genetic polymorphisms associated with innate immune factors and HIV-1.

Sobieszczyk ME, Lingappa JR, McElrath MJ.

Curr Opin HIV AIDS. 2011 Sep;6(5):427-34. doi: 10.1097/COH.0b013e3283497155. Review.

PMID:
21734565
32.

Lessons drawn from recent HIV vaccine efficacy trials.

Fuchs JD, Sobieszczyk ME, Hammer SM, Buchbinder SP.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S128-31. doi: 10.1097/QAI.0b013e3181fbca02.

33.

Combining Google Earth and GIS mapping technologies in a dengue surveillance system for developing countries.

Chang AY, Parrales ME, Jimenez J, Sobieszczyk ME, Hammer SM, Copenhaver DJ, Kulkarni RP.

Int J Health Geogr. 2009 Jul 23;8:49. doi: 10.1186/1476-072X-8-49.

34.

Engaging members of African American and Latino communities in preventive HIV vaccine trials.

Sobieszczyk ME, Xu G, Goodman K, Lucy D, Koblin BA.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):194-201.

35.

Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study.

Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, Gao W, Hyman C, Cohen MH, Cole SR, Plankey MW, Levine AM, Justman J; Women's Interagency HIV Study.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):272-80. doi: 10.1097/QAI.0b013e31817af461.

PMID:
18545157
36.

The challenge of HIV-1 subtype diversity.

Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM.

N Engl J Med. 2008 Apr 10;358(15):1590-602. doi: 10.1056/NEJMra0706737. Review. No abstract available. Erratum in: N Engl J Med. 2008 Oct 30;359(18):1965-6. N Engl J Med. 2008 Oct 30;359(18):1972.

37.

Anaemia in acute HIV-1 subtype C infection.

Mlisana K, Auld SC, Grobler A, van Loggerenberg F, Williamson C, Iriogbe I, Sobieszczyk ME, Abdool Karim SS; CAPRISA Acute Infection Study Team.

PLoS One. 2008 Feb 20;3(2):e1626. doi: 10.1371/journal.pone.0001626.

38.

Advances in antiretroviral therapy.

Sobieszczyk ME, Jones J, Wilkin T, Hammer SM.

Top HIV Med. 2006 Mar-Apr;14(1):36-62.

39.

Advances in antiretroviral therapy.

Sobieszczyk ME, Talley AK, Wilkin T, Hammer SM.

Top HIV Med. 2005 Mar-Apr;13(1):24-44.

40.

Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ.

J Antimicrob Chemother. 2004 Aug;54(2):566-9. Epub 2004 Jul 21.

PMID:
15269195

Supplemental Content

Loading ...
Support Center